Want to see CNMD full AI Analyst Report?
CNMD Stock Chart & Stats
$50.48
$0.19(0.28%)
At close: 4:00 PM EST
$50.48
$0.19(0.28%)
Day’s Range― - ―
52-Week Range$31.44 - $56.64
Previous CloseN/A
Volume49.43K
Average Volume (3M)425.99K
Market Cap
$1.48B
Enterprise Value$1.78K
Total Cash (Recent Filing)$37.33M
Total Debt (Recent Filing)$834.25M
Price to Earnings (P/E)26.6
Beta0.65
Next Earnings
Oct 28, 2026Next Dividend Ex-DateN/A
Dividend Yield1.62%
Share Statistics
EPS (TTM)1.85
Shares Outstanding29,951,248
10 Day Avg. Volume269,309
30 Day Avg. Volume425,988
Financial Highlights & Ratios
PEG Ratio-0.41
Price to Book (P/B)1.22
Price to Sales (P/S)0.92
P/FCF Ratio8.35
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$45.25Price Target Upside-10.36% Downside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)4.34
Revenue Forecast (FY)$1.36B
Bulls Say, Bears Say
Bulls Say
Recurring Procedure-Driven RevenueCONMED’s disposable products create recurring revenue tied to surgical procedures, while installed capital equipment supports compatible consumables. This model can improve customer retention and revenue visibility as hospital, ASC and physician-office procedure volumes expand.
Organic Growth And Product AdoptionBroad organic growth across general and orthopedic surgery, alongside adoption of BioBrace and other growth products, supports CONMED’s ability to expand its installed customer base. Management’s 5%–6% organic growth outlook indicates continued underlying demand.
Smoke Evacuation Regulatory TailwindsExpanding surgical smoke evacuation requirements create a structural demand driver for Buffalo Filter products. Regulation can accelerate hospital adoption, enlarge the addressable market and support recurring consumable sales as facilities upgrade operating-room safety practices.
Bears Say
Compressed And Volatile ProfitabilityAlthough gross margins remain healthy, lower operating and net margins indicate weaker earnings conversion from revenue. The sharp EPS decline leaves less buffer against cost, product-mix or pricing pressure and makes sustained margin recovery important to long-term financial performance.
Meaningful Leverage And Interest BurdenDebt refinancing improved maturity management but did not eliminate balance-sheet risk. Limited cash relative to obligations and higher expected interest expense can constrain investment, acquisitions and shareholder returns if operating profitability or procedure volumes weaken.
Uneven Cash ConversionPositive cash generation is offset by variable working-capital needs and only moderate operating-cash-flow coverage of debt. Reduced full-year FCF expectations could slow deleveraging and leave CONMED more dependent on consistent earnings and disciplined inventory management.
Conmed News
CNMD FAQ
What was Conmed’s price range in the past 12 months?
Conmed lowest stock price was $31.44 and its highest was $56.63 in the past 12 months.
What is Conmed’s market cap?
Conmed’s market cap is $1.48B.
When is Conmed’s upcoming earnings report date?
Conmed’s upcoming earnings report date is Oct 28, 2026 which is in 52 days.
How were Conmed’s earnings last quarter?
Conmed released its earnings results on Jul 29, 2026. The company reported $1.38 earnings per share for the quarter, beating the consensus estimate of $1.11 by $0.27.
Is Conmed overvalued?
According to Wall Street analysts Conmed’s price is currently Overvalued.
Does Conmed pay dividends?
Conmed pays a Quarterly dividend of $0.2 which represents an annual dividend yield of 1.62%. See more information on Conmed dividends here
What is Conmed’s EPS estimate?
Conmed’s EPS estimate is 1.
How many shares outstanding does Conmed have?
Conmed has 29,951,248 shares outstanding.
What happened to Conmed’s price movement after its last earnings report?
Conmed reported an EPS of $1.38 in its last earnings report, beating expectations of $1.11. Following the earnings report the stock price went up 8.725%.
Which hedge fund is a major shareholder of Conmed?
Currently, no hedge funds are holding shares in CNMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Conmed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$45.25 (-10.36% Downside)
$45.25 (-10.36% Downside)
Blogger Sentiment
Bullish
CNMD Sentiment 60%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 53.9K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.47%
12-Months-Change
Fundamentals
Return on Equity
1.62%
Trailing 12-Months
Asset Growth
-1.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Conmed
CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfolio includes specialized orthopedic surgical items, such as the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and PopLok Knotless Suture Anchors. These innovative offerings provide unique clinical advantages to orthopedic surgeons for repairing soft tissue injuries and are complemented by supportive tools that facilitate minimally invasive sports medicine operations. These orthopedic solutions are marketed under prominent brand names, including Hall, CONMED Linvatec, Concept, and Shutt. Furthermore, CONMED supplies general surgical equipment, encompassing items for clinical insufflation, smoke evacuation, electrosurgical interventions, and endomechanical applications. Its endoscopic technology segment provides both diagnostic and therapeutic instruments utilized in gastroenterological procedures, alongside products specifically designed for addressing conditions of the biliary system. The company also offers cardiac monitoring solutions, featuring ECG and EEG electrodes, and pads for cardiac defibrillation. CONMED distributes its diverse range of products directly to a wide array of healthcare facilities, including hospitals and surgical centers, and also leverages specialized medical distributors. Established in 1970, CONMED Corporation maintains its corporate headquarters in Largo, Florida.
CNMD Company Deck
CNMD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed predominantly positive operational and financial progress: organic revenue growth exceeded expectations (+6% organic), adjusted EPS rose 20% driven partly by a one-time tariff refund, gross margins and operating margins expanded, free cash flow in Q2 increased materially (+46% YoY), key growth products (Buffalo Filter, BioBrace, AirSeal) advanced with regulatory and clinical tailwinds, portfolio optimization and a meaningful refinancing were completed, and experienced leadership additions were made. Offsetting items included AirSeal growth below near-term expectations, flat U.S. orthopedics, higher expected interest expense and tax rate, a lowered top-end of revenue guidance, and a reduced full-year free cash flow target driven by working capital. Overall, highlights outweigh the lowlights, but several non-recurring benefits and near-term headwinds temper the outlook.View all CNMD earnings summariesCNMD Stock 12 Month Forecast
Average Price Target
$45.25
▼(-10.36% Downside)
Technical Analysis
Artivion
―
Integra Lifesciences
―
Ufp Technologies
―
AdaptHealth
―
PROCEPT BioRobotics
―
Ownership Overview
0.19% Insiders
40.03% Mutual Funds
25.77% Other Institutional Investors
3.51% Public Companies and
Individual Investors